Overview
ISO 11979-5:2020 - "Ophthalmic implants - Intraocular lenses - Part 5: Biocompatibility" specifies requirements and guidance for the biocompatibility evaluation of intraocular lens (IOL) materials. It addresses material selection, processing conditions, physicochemical characterization, biological testing and guidance for an ocular implantation test. The standard is risk‑based and intended to support safe design, manufacture and regulatory compliance of IOLs.
Key technical topics and requirements
- Risk‑based evaluation: Follow ISO 14971 for risk management and integrate test data into a biological risk–benefit assessment.
- Physicochemical characterization: Mandatory tests include:
- Exhaustive extraction - identify/quantify extractables and residues (Annex A).
- Leachables - identify substances released under simulated physiological conditions (Annex B).
- Hydrolytic stability - assess aqueous degradation and impact on transmittance/dioptric power (Annex C).
- Photostability (UV/Vis) - evaluate optical, mechanical and chemical effects of irradiation; lens power and image quality measurements required (Annex D).
- Nd‑YAG laser exposure - evaluate effects of laser treatment on material chemistry (Annex E).
- Insoluble inorganics - quantify particulate/inorganic contaminants from processing/packaging.
- Biological tests (aligned with ISO 10993):
- Cytotoxicity, sensitization, genotoxicity and local effects after implantation (Clauses 6.2–6.5).
- Ocular implantation test with guidance on duration and methodology (Annex G). Note: the 2020 edition reduced rabbit ocular implantation duration to 3 months and extended some implantation durations to 3 months in Annex F.
- Use of state‑of‑the‑art analytical methods and a documented biological evaluation plan. Representative sample allowances for physicochemical and biological testing are defined (Tables 1–2).
Practical applications and who uses it
ISO 11979-5:2020 is used by:
- IOL manufacturers for material selection, process validation and pre‑market submissions.
- Regulatory affairs and notified bodies evaluating device safety dossiers.
- Medical device testing laboratories conducting physicochemical and biological assays.
- R&D and quality teams assessing new materials, design modifications or sterilization effects.
- Clinicians and researchers referencing safety evidence for novel IOL designs.
Benefits include clearer pathways for demonstrating biocompatibility, harmonized testing expectations, and better alignment with ISO 10993 biological evaluation frameworks.
Related standards
- ISO 10993 series (biological evaluation of medical devices)
- ISO 11979‑1, ‑2, ‑3 (IOL vocabulary, optical and mechanical tests)
- ISO 14971 (risk management)
- ISO/TR 22979 (guidance on IOL design modifications)
Keywords: ISO 11979-5:2020, intraocular lens biocompatibility, IOL testing, physicochemical tests, ocular implantation test, ISO 10993, ISO 14971.
